A paradoxical cerebral hemodynamic effect of hydralazine.
Hydralazine is shown to have a very complex cerebral hemodynamic effect. It raises the intracranial pressure which, together with its effect upon systemic blood pressure, reduces the cerebral perfusion pressure. In spite of this and a concomitantly induced hyperventilation by hydralazine, CBF increases with some delay. The conclusion is that hydralazine is a cerebral vasodilator acting immediately upon cerebral capacitance vessels but later upon the resistance vessels as well.
D000293:Adolescent; D000804:Angiotensin II / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001929:Brain Edema / Q000209:etiology; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000209:etiology; D003864:Depression, Chemical; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy; D007263:Infusions, Parenteral; D007427:Intracranial Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D013268:Stimulation, Chemical; D014294:Trimethaphan / Q000494:pharmacology; D014980:Xenon Radioisotopes
D014980:Xenon Radioisotopes; D000804:Angiotensin II; D006830:Hydralazine; D014294:Trimethaphan